Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma

MT Newswires Live06-11 21:02

Alpha Tau Medical (DRTS) said Thursday the US Food and Drug Administration has cleared the enrollment of seven more patients and addition of two US clinical sites for its Alpha DaRT trial in recurrent glioblastoma.

The regulator issued the clearance after reviewing interim safety data from the first three patients treated in the study, the company said, adding it intends to immediately proceed with the enrollment of the final seven participants for the study.

The company said in May that interim results from three patients showed 100% local disease control, including a 67% complete response rate with no unexpected safety signals.

Shares of Alpha Tau Medical were up 2% in premarket activity Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642282415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642282415","market":"sh","top_or_hot":-1,"title":"Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> (DRTS) said Thursday the US Food and Drug Administration has cleared the enrollment of seven more patients and addition of two US clinical sites for its Alpha DaRT trial in recurrent glioblastoma.</p><p>The regulator issued the clearance after reviewing interim safety data from the first three patients treated in the study, the company said, adding it intends to immediately proceed with the enrollment of the final seven participants for the study.</p><p>The company said in May that interim results from three patients showed 100% local disease control, including a 67% complete response rate with no unexpected safety signals.</p><p>Shares of <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> Medical were up 2% in premarket activity Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Tau Medical Says FDA Clears Additional Patients, Sites for Alpha DaRT Trial in Glioblastoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> (DRTS) said Thursday the US Food and Drug Administration has cleared the enrollment of seven more patients and addition of two US clinical sites for its Alpha DaRT trial in recurrent glioblastoma.</p><p>The regulator issued the clearance after reviewing interim safety data from the first three patients treated in the study, the company said, adding it intends to immediately proceed with the enrollment of the final seven participants for the study.</p><p>The company said in May that interim results from three patients showed 100% local disease control, including a 67% complete response rate with no unexpected safety signals.</p><p>Shares of <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> Medical were up 2% in premarket activity Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642282415","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642282415","pubTimestamp":1781182954,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alpha Tau Medical  said Thursday the US Food and Drug Administration has cleared the enrollment of seven more patients and addition of two US clinical sites for its Alpha DaRT trial in recurrent glioblastoma.The regulator issued the clearance after reviewing interim safety data from the first three patients treated in the study, the company said, adding it intends to immediately proceed with the enrollment of the final seven participants for the study.The company said in May that interim results from three patients showed 100% local disease control, including a 67% complete response rate with no unexpected safety signals.Shares of Alpha Tau Medical were up 2% in premarket activity Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4588":"碎股","BK4585":"ETF&股票定投概念","DRTS":"Alpha Tau Medical","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Alpha Tau Medical表示FDA批准了更多患者和Alpha DaRT胶质母细胞瘤试验地点","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"DRTS":1.5},"content_text":"Alpha Tau Medical (DRTS) said Thursday the US Food and Drug Administration has cleared the enrollment of seven more patients and addition of two US clinical sites for its Alpha DaRT trial in recurrent glioblastoma.The regulator issued the clearance after reviewing interim safety data from the first three patients treated in the study, the company said, adding it intends to immediately proceed with the enrollment of the final seven participants for the study.The company said in May that interim results from three patients showed 100% local disease control, including a 67% complete response rate with no unexpected safety signals.Shares of Alpha Tau Medical were up 2% in premarket activity Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642282415","isCrawlerRequest":true}